ArticleThe journal of allergy and clinical immunology. Global2026
Serum baseline tryptase levels across chronic kidney disease stages: A retrospective report.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) has been associated with elevated serum baseline tryptase (sBT) levels, which may exceed the standard reference value of less than 11.5 ng/mL as kidney function declines. Objective: This study aimed to characterize sBT levels across different CKD stages in a United States-based cohort. Methods: We conducted a retrospective chart review of consecutive nephrology outpatients across the Mayo Clinic enterprise from January 2020 to July 2025. Patients with a confirmed CKD diagnosis ( Results: A total of 96 patients met the inclusion criteria. The median sBT levels (ng/mL) by CKD stage were as follows: stage 1, 3.3 (interquartile range [IQR] = 0.0); stage 2, 5.6 (IQR = 3.9); stage 3a, 7.6 (IQR = 4.35); stage 3b, 6.3 (IQR = 2.8); and stage 4, 11.1 (IQR = 4.35). A statistically significant difference was observed in the distribution of sBT levels across CKD stages (χ Conclusion: A statistically significant association between CKD stage and serum baseline tryptase level has been observed, suggesting that declining kidney function may influence circulating tryptase concentrations. This finding highlights the importance of accounting for renal function when interpreting elevated sBT values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.